SPA
OLMA icon

Sherbrooke Park Advisers’s Olema Pharmaceuticals OLMA Stock Holding History

Sherbrooke Park Advisers’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,212
Closed -$127K – 1124
2024
Q1 		$127K Buy
+11,212
New +$145K 0.02% 782

Other funds holding OLMA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Sherbrooke Park Advisers's OLMA Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of Olema Pharmaceuticals (OLMA) in Q2 2024, closing a stake of 11,212 shares — an estimated $127K sold.

Sherbrooke Park Advisers first reported a position in OLMA in Q1 2024 and held it in 1 quarter. The position peaked at $127K in Q1 2024. 128 funds tracked by Wall St. Rank hold OLMA as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining Olema Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 11,212 Olema Pharmaceuticals shares in Q2 2024, an estimated $127K.
  • Sherbrooke Park Advisers first reported a position in Olema Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Olema Pharmaceuticals position peaked at $127K in Q1 2024.
  • 128 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.